Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy

Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix for EDS related to OSAS and for narcolepsy types 1 and 2. The approval of pitolisant in Japan is based on domestic Phase III studies and international clinical research evidence. Wakix is an orally administered therapy that modulates sleep–wake pathways. Credit: eldar nurkovic / Shutterstock.com. Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related to obstructive sleep apnoea syndrome (OSAS) and for narcolepsy types 1 and 2. The approval covers patients with OSAS who continue to experience EDS while receiving…

Source: Pharmaceutical Technology